1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBiomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (U01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). Funding opportunity for observational studies on biomarkers of cognitive decline in individuals with Autism Spectrum Disorder.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum Agency: National Institutes of Health Assistance Listings: 93. 866 -- Aging Research Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to conduct observational studies in individuals living with Autism Spectrum Disorders (ASD) along the lifespan.
The overarching goal is to determine the occurrence of age-related neurodegeneration across the heterogeneities of the ASD spectrum, characterize the physiopathology and manifestation of Alzheimer's disease (AD) and AD-related dementias (ADRD) in ASD, and, ultimately, develop precision-medicine strategies tailored to this understudied population.
It is expected that proposed studies pursue deep phenotyping of aging individuals across the ASD spectrum, along with the characterization/validation of existing biomarkers of age-related cognitive decline and/or dementia in this population, and/or the discovery of novel ones. Applications are not being solicited at this time.
Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code.
This NOFO encourages collaborations between investigators with expertise in autism and those with expertise in aging and dementia, fostering interactions between established centers for neurodevelopmental research and centers studying age-related cognitive decline.
Private institutions of higher education Independent school districts Public and state institutions of higher education For-profit organizations other than small businesses Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Federally recognized Native American tribal governments Public and Indian housing authorities Grantor contact information Alessandra Rovescalli, Ph. D.
National Institute on Aging (NIA) No documents are currently available. Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Universities, research institutions, and nonprofit organizations. Confirm the full requirements in the official notice before applying.
Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (U01 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
BrainCheck Pilot Grant is sponsored by BrainCheck. The BrainCheck Pilot Grant supports early-stage, high-impact research that expands possibilities in Alzheimer's disease and related dementias (ADRD), including detection, assessment, care planning, and trial access. It focuses on projects that advance cognitive screening, increase population diversity representation, expand remote or community-based access to cognitive evaluation, integrate digital and biological biomarkers, and support earlier detection.
NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute on Aging (NIA) - NIH. NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute o…
Human Cognitive and Behavioral Science — Request for Applications, Ph.D. is sponsored by Simons Foundation Autism Research Initiative (SFARI). This RFA prioritized research that produces foundational knowledge about neurobehavioral differences associated with Autism Spectrum Disorder (ASD), with an emphasis on objective, quantitative measures for translational efforts like biomarkers and outcome measures.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article